← Leaderboards
Yuqing Huo
University Of Minnesota Twin Cities
$8,590,587
Attributed
$12,683,193
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,683,193 · 8
By mechanism
R01$12,278,193 · 7
R21$405,000 · 1
Top collaborators
- Ruth B. Caldwell14 shared
- Yunchao Su4 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Robert T Tranquillo$20,629,815
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsDesignMediatingMacrophageProductionEndothelial CellsLesionEnzymesBlood VesselsMyeloid CellsInflammatoryIn VivoMyelogenousIn VitroGeneticBone MarrowOverexpressionSignal TransductionEndotheliumRetinal AngiogenesisOxygenPlayMolecularGlycolysis
Grant awards (34)
Adenosine receptor 2A in subretinal fibrosis$402,276
R01 · FY2025 · EY · contact PI
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2025 · EY
Adenosine receptor 2A in subretinal fibrosis$437,751
R01 · FY2024 · EY · contact PI
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2024 · EY
Myeloid glycolysis in pathological ocular angiogenesis$452,760
R01 · FY2023 · EY
Adenosine receptor 2A in subretinal fibrosis$437,751
R01 · FY2023 · EY · contact PI
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2023 · EY
Myeloid glycolysis in pathological ocular angiogenesis$439,177
R01 · FY2022 · EY
Adenosine receptor 2A in subretinal fibrosis$437,751
R01 · FY2022 · EY · contact PI
"Myeloid PFKFB3 in subretinal fibrosis"$400,332
R01 · FY2022 · EY
Myeloid glycolysis in pathological ocular angiogenesis$355,411
R01 · FY2022 · EY
Myeloid glycolysis in pathological ocular angiogenesis$439,177
R01 · FY2021 · EY
PFKFB3 in vascular remodeling$570,088
R01 · FY2020 · HL
Myeloid glycolysis in pathological ocular angiogenesis$452,760
R01 · FY2020 · EY
PFKFB3 in vascular remodeling$570,088
R01 · FY2019 · HL
Myeloid glycolysis in pathological ocular angiogenesis$448,718
R01 · FY2019 · EY
PFKFB3 in vascular remodeling$570,088
R01 · FY2018 · HL
PFKFB3 in vascular remodeling$570,088
R01 · FY2017 · HL
The role of adenosine kinase in atherosclerosis$371,533
R01 · FY2015 · HL · contact PI
The role of adenosine kinase in atherosclerosis$370,764
R01 · FY2014 · HL · contact PI
The role of adenosine kinase in atherosclerosis$364,424
R01 · FY2013 · HL · contact PI
The role of neutrophil recruitment in arterial diseases$178,500
R21 · FY2013 · HL · contact PI
The role of adenosine kinase in atherosclerosis$332,428
R01 · FY2011 · HL · contact PI
The role of neutrophil recruitment in arterial diseases$177,518
R21 · FY2011 · HL · contact PI
The role of adenosine kinase in atherosclerosis$52,694
R01 · FY2011 · HL · contact PI
The role of neutrophil recruitment in arterial diseases$48,982
R21 · FY2011 · HL · contact PI
Leukocyte C2GIcNAcT-I in atherosclerosis$362,911
R01 · FY2009 · HL · contact PI
Leukocyte C2GIcNAcT-I in atherosclerosis$362,911
R01 · FY2008 · HL · contact PI
Leukocyte C2GIcNAcT-I in atherosclerosis$362,911
R01 · FY2007 · HL · contact PI
Inhibition of leukocyte C2GlcNAcT--l reduces thrombosis$281,609
R01 · FY2007 · HL · contact PI
Leukocyte C2GIcNAcT-I in atherosclerosis$358,900
R01 · FY2006 · HL · contact PI
Inhibition of leukocyte C2GlcNAcT--l reduces thrombosis$290,021
R01 · FY2006 · HL · contact PI
Inhibition of leukocyte C2GlcNAcT--l reduces thrombosis$297,000
R01 · FY2005 · HL
Inhibition of leukocyte C2GlcNAcT--l reduces thrombosis$284,875
R01 · FY2004 · HL